GLP1RYour two copies: rs10305420C/rs10305420C
CCTypical response
The receptor that semaglutide and other GLP-1 drugs act on.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Weight managementExample report
Retatrutide
Use with caution
Your GIPR gene raises your chance of nausea or vomiting on retatrutide: roughly 4.4% of people with your genotype vomit, compared with about 2.5% at the lowest risk. Semaglutide is not affected by this gene.
The genes behind this label
The guidelines read 2 genes for retatrutide. Each card shows the two copies this person inherited and what they mean.
GIPRYour two copies: rs1800437C/rs1800437G
Decreased function
One copy works and one works less well.
A gut-hormone receptor that tirzepatide and retatrutide act on.
This result changes the label.
What the guidelines say
What each guideline says about your result.
GLP1RTypical responseGIPRDecreased function
Gene2Rx research summary, both genes together
Evidence: weakSee the drug page (Gene2Rx research summaries, opens in a new tab)
- In plain words
- Your GIPR gene raises your chance of nausea or vomiting on retatrutide: roughly 4.4% of people with your genotype vomit, compared with about 2.5% at the lowest risk. Semaglutide is not affected by this gene.
- What it means
- GLP1R: the more common Pro7/Pro7 form of the signal peptide (rs10305420 C/C). GIPR: one copy of the Gln354 partial loss-of-function allele (rs1800437 G/C). No pharmacogenetic study of retatrutide exists; by extrapolation from the tirzepatide data this pair is expected to carry roughly 1.8-fold the odds of moderate-to-severe vomiting seen with the lowest-risk genotype pair. Expected weight-loss efficacy from the GLP1R arm of retatrutide. The GIPR component of this risk is specific to dual GIP/GLP-1 agonists and does not apply to semaglutide.
- What the research suggests
- Use standard dosing but consider a slower dose-escalation schedule, and counsel on the elevated chance of nausea and vomiting. If GI symptoms are intolerable, a GLP1R-only agonist such as semaglutide is unaffected by the GIPR variant and may be better tolerated.
Gene2Rx guideline extrapolated from the tirzepatide results in Su et al., Nature (2026). Retatrutide, an investigational GIP, GLP-1 and glucagon receptor agonist, has no genetic study of its own, so this assumes the GLP1R and GIPR variants act as they do with tirzepatide, which also acts on both receptors.
Gene2Rx reads your GLP1R and GIPR results together for retatrutide, so this label reflects both genes.
About retatrutide
Retatrutide is an investigational weight-loss medicine from Eli Lilly that acts on three hormone receptors: GLP-1, GIP and glucagon.
Others in weight management
Compare all 3 weight managementDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.